Professional view

levofloxacin hemihydrate: prescribing and clinical use

Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.

levofloxacin hemihydrate: clinical details

Prescribing considerations

Reserve systemic and inhaled levofloxacin for infections where commonly recommended alternatives are inappropriate because of resistance, contraindication, intolerance or failure.
Confirm the formulation-specific indication and use microbiology, susceptibility and local resistance information where available.
Review previous serious quinolone reactions, tendon risk, seizure susceptibility, renal function, QT risk, dysglycaemia risk and aortic or heart-valve risk.
Avoid concomitant systemic corticosteroids where possible. Consider cumulative QT and seizure-threshold effects.
For Quinsair, assess baseline respiratory status and possible treatment-related bronchospasm.

Contraindications and cautions

Hypersensitivity to levofloxacin, another quinolone or relevant excipients.
For selected systemic and inhaled products: epilepsy, previous fluoroquinolone-related tendon disorder, pregnancy and breastfeeding.
Selected systemic products are contraindicated in children and growing adolescents; Quinsair is licensed for adults. Eye drops are not recommended below one year.
Contraindications vary by route, particularly for ocular products; check the product-specific SmPC.

Monitoring

Renal function before and during systemic treatment when clinically indicated.
Clinical response, culture results and emergence of resistance or superinfection.
Tendon, musculoskeletal, peripheral neurological, psychiatric and sensory symptoms; promptly discontinue systemic or inhaled treatment if serious reactions arise.
Blood glucose in people with diabetes; coagulation in patients taking vitamin K antagonists.
ECG and electrolytes when clinically indicated by QT risk; liver tests and blood count if compatible symptoms or abnormalities develop.
Respiratory symptoms and pulmonary function with inhaled treatment; eye response and signs of allergy, irritation or treatment failure with ocular treatment.

Clinical pharmacology

Levofloxacin is the active L-isomer of ofloxacin and inhibits bacterial DNA gyrase and topoisomerase IV. Oral absorption is high, metabolism is limited and elimination is predominantly renal. Ocular administration produces much lower systemic exposure; inhalation produces high airway concentrations with variable systemic absorption.

Formulation and product differences

Tablets provide systemic exposure and can be taken with or without food, but polyvalent cations and sucralfate reduce absorption.
Infusion is a systemic, ready-to-use solution requiring controlled intravenous administration and product-specific compatibility checks.
Quinsair is a single-use nebuliser solution for chronic Pseudomonas pulmonary infection in adults with cystic fibrosis and must use the specified Zirela system.
Oxalux is a preservative-free single-dose eye-drop presentation. The selected multidose eye drops contain benzalkonium chloride, which can irritate the eye and affect soft contact lenses.